HIV: how to manage heavily treatment-experienced patients.
HIV
HIV resistance
antiretroviral therapy
treatment experienced
Journal
Drugs in context
ISSN: 1745-1981
Titre abrégé: Drugs Context
Pays: England
ID NLM: 101262187
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
09
2021
accepted:
10
12
2021
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
Although decreasing in prevalence, heavily treatment-experienced (HTE) persons with limited options for HIV treatment present unique complexities, even amongst experienced providers, as there is no single approach to successful management. HTE patients are described as those having two or less antiretroviral (ARV) classes available for use with limited fully active ARV agents within each class. A detailed understanding of the underlying processes that caused previous treatment failures, diagnostics to define resistance, resistance mechanisms and ARV pharmacology should all function in tandem to determine the next steps of clinical care. This narrative review provides an overview of the clinician approach to care, including diagnostics, approaches to regimen creation, relevant resources, and a broad array of both currently available and upcoming ARVs that may be used in regimens for HTE patients.
Identifiants
pubmed: 35310298
doi: 10.7573/dic.2021-9-1
pii: dic-2021-9-1
pmc: PMC8903874
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
Copyright © 2022 Spivack S, Pagkalinawan S, Samuel R, Koren DE.
Déclaration de conflit d'intérêts
Disclosure and potential conflicts of interest: DEK has participated on advisory panels for Gilead, Janssen, Thera and ViiV and served as an independent consultant for Abbvie and Thera. The remaining authors report no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/12/dic.2021-9-1-COI.pdf
Références
Ann Pharmacother. 2021 Jun;55(6):792-797
pubmed: 32964736
PLoS Med. 2016 Nov 29;13(11):e1002183
pubmed: 27898679
Antivir Ther. 2009;14(6):859-64
pubmed: 19812449
Antimicrob Agents Chemother. 2003 Nov;47(11):3478-84
pubmed: 14576105
AIDS. 2020 Nov 15;34(14):2051-2059
pubmed: 33055569
Drugs. 2012 Apr 16;72(6):847-69
pubmed: 22512366
Clin Infect Dis. 2019 Feb 1;68(4):535-544
pubmed: 30184165
Am J Health Syst Pharm. 2009 Apr 15;66(8):715-26
pubmed: 19336831
Lancet. 2013 Aug 24;382(9893):700-8
pubmed: 23830355
J Infect Dis. 2014 Aug 1;210(3):354-62
pubmed: 24446523
Lancet HIV. 2020 Nov;7(11):e740-e751
pubmed: 33128903
Curr Opin HIV AIDS. 2018 Jul;13(4):354-358
pubmed: 29746266
Drugs Today (Barc). 2020 Feb;56(2):113-124
pubmed: 32163527
Ann Intern Med. 2001 Mar 20;134(6):440-50
pubmed: 11255519
Lancet HIV. 2018 May;5(5):e211-e220
pubmed: 29592840
New Microbiol. 2004 Apr;27(2 Suppl 1):31-9
pubmed: 15646062
AIDS. 2009 Nov 13;23(17):2289-300
pubmed: 19710593
Clin Lab Med. 2002 Sep;22(3):637-49
pubmed: 12244590
Ther Clin Risk Manag. 2008 Aug;4(4):759-66
pubmed: 19209258
Antimicrob Agents Chemother. 2020 Mar 24;64(4):
pubmed: 31988104
N Engl J Med. 2018 Aug 16;379(7):645-654
pubmed: 30110589
J Transl Med. 2011 Jan 27;9 Suppl 1:S5
pubmed: 21284904
J Acquir Immune Defic Syndr. 2020 Dec 15;85(5):635-642
pubmed: 32925358
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30885900
Antivir Ther. 2019;24(6):467-471
pubmed: 31172977
Clin Infect Dis. 2009 Nov 1;49(9):1441-9
pubmed: 19814627
Lancet Infect Dis. 2013 Jul;13(7):587-96
pubmed: 23664333
Lancet HIV. 2020 Mar;7(3):e164-e172
pubmed: 31911147
N Engl J Med. 2003 May 29;348(22):2175-85
pubmed: 12637625
AIDS Rev. 2008 Jul-Sep;10(3):131-42
pubmed: 18820715
Ann Pharmacother. 2016 Nov;50(11):942-952
pubmed: 27465879
Lancet. 2007 Apr 7;369(9568):1169-78
pubmed: 17416261
N Engl J Med. 2008 Oct 2;359(14):1429-41
pubmed: 18832244
HIV Clin Trials. 2008 Mar-Apr;9(2):83-90
pubmed: 18474493
Curr Opin HIV AIDS. 2021 May 1;16(3):148-151
pubmed: 33797433
J Antimicrob Chemother. 2011 Apr;66(4):709-12
pubmed: 21393164